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Vaccines aiming to promote T-cell-mediated immune responses have so far showed 
limited efficacy, and there is a need for novel strategies. Studies indicate that autophagy 
plays an inherent role in antigen processing and presentation for CD4+ and CD8+ T cells. 
Here, we report a novel vaccine strategy based on fusion of antigen to the selective 
autophagy receptor sequestosome 1 (SQSTM1)/p62. We hypothesized that redirection 
of vaccine antigen from proteasomal degradation into the autophagy pathway would 
increase the generation of antigen-specific T cells. A hybrid vaccine construct was 
designed in which the antigen is fused to the C-terminus of p62, a signaling hub, and a 
receptor that naturally delivers ubiquitinated cargo for autophagic degradation. Fusion 
of the human immunodeficiency virus-1 antigen Gagp24 to p62 resulted in efficient 
antigen delivery into the autophagy pathway. Intradermal immunization of mice revealed 
that, in comparison to Gagp24 delivered alone, fusion to p62 enhanced the number of 
Gagp24-specific interferon-γ-producing T cells, including CD8+ T cells. The strategy may 
also have the potential to modulate the antigenic peptide repertoire. Because p62 and 
autophagy are highly conserved between species, we anticipate this strategy to be a 
candidate for the development of T-cell-based vaccines in humans.
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inTrODUcTiOn
T-cell-based vaccines have the potential to confer protection against cancer and pathogens. CD4+ 
T cells may lead to the killing of target cells in an indirect or direct manner (1–3), and they are crucial 
for the generation of long-lived, memory CD8+ T cells (4–6). CD8+ T cells kill in a direct manner, and 
several studies have proven their ability to fight pathogens and reject cancer (7, 8). However, vaccines 
aiming to promote T-cell-mediated immune responses have so far showed limited efficacy. Thus, 
development of technologies that can improve T cell responses, in particular CD8+ T cell responses, 
is a major goal in vaccine design and immunotherapy.
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Antigen-presenting cells (APCs) present peptides on major 
histocompatibility complex (MHC) class I molecules to CD8+ 
T  cells and on MHC class II molecules to CD4+ T cells. For 
presentation on MHC class II molecules, extracellularly or intra-
cellularly derived antigenic protein fragments are generated in 
endolysosomal compartments and peptides are loaded on MHC 
class II molecules in late endosomes/MHC class II molecule-
containing compartments (MIIC) (9). The conventional pathway 
for MHC class I antigen presentation includes proteasomal 
degradation in the cytosol of APC and transporter associated 
with antigen processing (TAP)-mediated delivery of peptides into 
the lumen of endoplasmic reticulum. There, peptides are loaded 
on MHC class I before transport of the peptide/MHC complex 
to the cell surface (10). The mechanism, whereby extracellular 
antigens are presented by APCs on MHC class I, is termed cross-
presentation. The specific mechanisms are still debated but may 
involve export of endocytosed antigen into the cytosol for further 
degradation and loading of peptides on MHC class I molecules in 
the endoplasmic reticulum or in endosomes (10–12).
A number of studies have pointed to the role of autophagy and 
autophagy proteins in antigen delivery and adaptive immunity 
(12–19). Autophagy is an intracellular degradation system that 
delivers constituents to the lysosome. During macroautophagy 
(hereafter autophagy) cytosolic proteins, damaged and superflu-
ous organelles, as well as invasive microorganisms are sequestered 
into a double-membrane vesicle called autophagosome, which 
undergoes fusion with endolysosomal compartments (20). Thus, 
the autophagic pathway facilitates presentation of cytoplasm-
derived antigens on MHC class II molecules (13, 21–25).
Several studies also suggest a role for autophagy in MHC 
class I-restricted antigen presentation and engagement of CD8+ 
T cells. For example, it has been shown that autophagy in the APC 
can enhance MHC class I-restricted presentation of endogenous, 
cytoplasm-derived, and cross-presented antigens (17, 26, 27). In 
addition, autophagy in the antigen donor cell has been implicated 
in enhanced cross-priming of CD8+ T cells and improved protec-
tion against cancer in mouse models (17, 28–31). Finally, the use 
of enriched autophagic vesicles as source of antigen suggested that 
such vesicles can contribute to cross-presentation of antigens to 
CD8+ T cells (28, 30, 31). Taken together, several studies indicate 
that autophagy plays an inherent role in antigen processing and 
presentation for CD4+ and CD8+ T cell activation.
Aiming to develop a vaccine with enhanced T cell priming 
capacity, we hypothesized that targeting of vaccine antigen to 
the autophagy pathway would promote antigen-specific T cell 
responses and mimic how APCs naturally encounter an infec-
tion or a cancerous cell. In order to target vaccine antigen to the 
autophagy pathway, we utilized sequestosome 1 (SQSTM1)/p62. 
We chose p62 because it is a selective autophagy receptor that 
naturally delivers a broad range of ubiquitinated cargo into the 
autophagy pathway, and we anticipated that it would tolerate 
fusion with various antigens (32–35). Furthermore, p62 medi-
ates NF-κB-activation, which could be beneficial for vaccine 
responses (36–38).
In this study, p62 was fused to the human immunodeficiency 
virus-1 (HIV-1) antigen Gagp24. Although many studies have 
suggested that CD8+ T cell responses against Gagp24 or its 
precursor Gag are important to maintain a low viral load and 
delay the onset of AIDS (39–43), conventional Gag-based vaccine 
strategies have failed to induce protective T cell responses. Thus, 
we wanted to explore the potential of an autophagy receptor and 
hypothesized that fusion of p62 to HIV-1 Gagp24 would rescue 
the antigen from rapid proteasomal degradation and potentiate 
antigen-specific T cell responses.
MaTerials anD MeThODs
reagents
The following reagent was obtained through the Centre for AIDS 
Reagent, Division of Virology, NIBSC, UK: HIV-1 Con B Gag 
peptides (ARP7111) from the Division of AIDS, NIAID, USA. 
The peptides comprise HIV-1 HXB2 Gagp24 and are 15-mers 
with 11-amino acid overlaps between sequential peptides.
cell lines and cultivation
HEK293 cells stably transfected with EGFP–LC3, denoted EGFP–
LC3+ 293 cells, were kindly provided by Sharon Tooze (Francis 
Crick Institute, London, UK) (44). EGPF-LC3+ 293 cells and 
HEK293T cells were cultured in RPMI 1640 (Life Technologies, 
Carlsbad, CA, USA) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS) (Biochrom AG, Berlin, Germany), 
0.1 μM non-essential amino acids (Lonza, Basel, Switzerland), 
1  mM sodium pyruvate (Lonza), 50  μM monothioglycerol 
(Sigma-Aldrich, St. Louis, MO, USA), and 40 mg/ml gensumycin 
(Sanofi-Aventis Norge AS, Lysaker, Norway) (herein, referred to 
as complete RPMI). For live-cell confocal microscopy, RPMI 1640 
without phenol red (Life Technologies) was used. All mammalian 
cells were grown at 37°C and 5% CO2.
Mice
Female C57BL/6 and BALB/c mice were purchased from Taconic 
(Ry, Denmark). All mice were acclimatized to the animal research 
facility Department of Comparative Medicine, Oslo University 
Hospital, Rikshospitalet and were included in experiments when 
they were 6–10  weeks of age. The study was approved by the 
National Committee for Animal Experiments, Norway (permit 
number: Id-4420), and the experiments were performed in 
accordance with the approved guidelines and regulations.
Plasmids and Design of constructs
pBudCE4.1 (Life Technologies) was used as an expression vector 
to retain the possibility of dual expression of genes in the future. 
For simple and versatile subcloning of all constructs in this study, 
we modified pBudCE4.1 and inserted a fragment containing the 
restriction sites 5′-HindIII–SalI–SfiI1–SfiI2–XbaI in the multiple 
cloning site downstream of the CMV promoter. The cDNA 
sequence of HIV-1 Gagp24, isolate BH10 (GenBank accession 
number M15654.1 and nucleotide 508–1200), was ordered from 
GenScript (Piscataway, NJ, USA) with SfiI restriction sites in the 
5- and 3-prime end (SfiI1: 5′ GGCCTCAGCGGCC TG- and SfiI2: 
GGCCTGCAGGGCC-3′). Human p62/SQSTM1 cDNA was 
retrieved by PCR from a pDEST-EGFP vector (Terje Johansen, 
Institute of Medical Biology, University of Tromsø, Norway) 
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by PCR and primers, including overhangs for HindIII (Pfwd: 
5′-AAATTTAAGCTTGATGGCGTCGCTCACCGTGAAG 
G-3′) and SalI (Prev: 5′-AAATTTGTCGACCTCAACGGCGGGG 
GATGCTTTGAATA-3′). cDNA encoding mCherry was ampli-
fied by PCR with primers, including overhangs for SfiI1 (Pfwd: 5′-AA 
ATTTGGCCTCAGCGGCC TGGTGAGCAAGGGCGAGGAGG 
AT-3′) and SfiI2 (Prev: 5′-AAATTTGGCCCTGCAGGCCTTAC 
TTGTACAG CTCGTCCATGCCG-3′). To conjugate Gagp24 
with mCherry, Gagp24 cDNA was amplified by PCR with prim-
ers, including overhangs for HindIII (Pfwd: 5′-AAATTTAAGC 
TTGATGCCCATCGTGCAGAACATCCAG-3′) and SalI (Prev: 
5′-AAATTTGTCGACCCCAGCACTCTAGCCTTATGG 
CC-3′). Plasmid encoding mCherry only was generated by PCR 
and primers that contained overhangs for HindIII (Pfwd: 5′-AA 
ATTTAAGCTTGATGGTGAGCAAGGGCGAGGAG-3′) and 
XbaI (Prev: 5′-AAATTTTCTAGACTT GTACAGCTCGTCCATG 
CCG-3′).
Dna Transfection for Transient  
Protein expression
All DNA plasmids were transfected into cells using Lipofectamine 
LTX with PLUS-reagent (Life Technologies). Cells were seeded 
at a density of 1000 cells/mm2 in 24-well plates or 8-well Nunc® 
Lab-Tek® II Chambered Coverglass (Sigma-Aldrich). Twenty-
four hours after seeding, the cells were transfected with 0.5 μg 
plasmid per well in 24-well plates, according to the manufac-
turer’s instructions (Life Technologies). Co-transfections of 
two plasmids were performed by using 0.25 μg DNA of each 
plasmid.
Western Blotting
For assessment of intracellular protein levels, cell cultures 
were washed in phosphate-buffered saline (PBS) (Lonza), and 
then lysed in CytoBuster™ protein extraction reagent (EMD 
Millipore, Billerica, MA, USA) on ice for 15 min. The lysates were 
cleared by 2000 × g centrifugation for 15 min at 4°C. Proteins 
were denatured by mixing 20 μl lysate with 4 μl sample loading 
solution [12% sodium dodecyl sulfate (SDS) with 3 mM Tris pH 
6.8 and 0.05% bromophenol blue], followed by incubation at 95°C 
for 5 min. The samples were run on a 4–12% Novex Tris-Glycine 
Gel (Life Technologies) and blotted onto an Immun-Blot™ 
PVDF membrane (Bio-Rad Laboratories, Hercules, CA, USA) 
in PBS with 0.1% tween. The membranes were blocked with 4% 
ECL Advance™ Blocking Reagent (GE Healthcare, Pittsburgh, 
PA, USA) at room temperature for 1.5 h. Afterward, the mem-
branes were incubated with a mouse monoclonal anti-HIV-1-p24 
antibody (0.5  μg/ml) (Abcam, Cambridge, UK) or a mouse 
monoclonal anti-β-tubulin antibody (0.5 μg/ml) (Abcam) at 4°C 
for 12 h. Next, the membrane was incubated with a horseradish 
peroxidase-conjugated rabbit anti-mouse IgG antibody (1 μg/ml) 
(Life Technologies) at room temperature for 1.5 h. Bound anti-
bodies were visualized using ECL Advance™ Western blotting 
detection kit (GE Healthcare, Little Chalfont, UK). Image acqui-
sition was performed using the ChemiDoc MP system (Bio-Rad 
Laboratories), and the bands were analyzed by ImageLab software 
version 4.1 (Bio-Rad Laboratories).
immunostaining
Cell cultures were washed once in PBS and fixed in 4% formal-
dehyde solution at 4°C for 45 min. To remove the fixative, cells 
were washed in PBS four times. Next, PBS containing 5% albumin 
and 0.05% saponin was used to reduce unspecific binding and 
to permeabilize the cells before immunostaining with a mouse 
monoclonal anti-HIV-1-p24 antibody (0.5 μg/ml) (Abcam) for 
2  h at room temperature, followed by three washes and a sec-
ondary staining for 1 h using goat anti-mouse conjugated with 
Alexa Fluor 568 (Abcam). Finally, the cells were washed and 
mounted using ProLong Gold Antifade Mountant with DAPI 
(Life Technologies).
Microscopy, sampling, and Quantitation
Confocal micrographs were taken with Olympus FluoView™ 
using an inverted FV1000 confocal microscope (Olympus 
America, Center Valley, PA, USA). The diode laser (405 nm) was 
used to excite DAPI, the argon laser (488 nm) to excite EGFP-
conjugates, and the helium–neon laser (543  nm) was used to 
excite mCherry and Alexa Fluor 568. All imaging experiments 
were performed three times. Images were systematically acquired 
throughout each slide in a uniform fashion. To quantitate the 
number of fluorescent puncta or vesicles and co-localization per 
cell, all images were counted. Representative images were chosen 
for publishing. Image editing was conducted in Image J and 
Adobe Illustrator CS5.
Dna Vaccination
For all in vivo experiments, DNA plasmids were prepared using 
large-scale EndoFree Qiagen kit (Qiagen, Hilden, Germany) and 
diluted to concentration 0.5 μg/μl in 0.9% NaCl. Mice were anes-
thetized, and their lower back was shaved before 25 μl plasmid 
solution was injected into the dermis on each flank (i.e., 12.5 μg 
DNA × 2 per mouse). Immediately afterward, the injection site 
was exposed to electroporation using DermaVax (BTX Harvard 
Apparatus, Holliston, MA, USA), applying two pulses of 450 V/
cm × 2.5 μs and eight pulses of 110 V/cm × 8.1 ms via a needle 
array electrode.
interferon-γ-elispot
Spleens from mice were crushed by a steel mesh to form single-
cell suspensions. In order to lyse the erythrocytes, the cell suspen-
sions were treated with 140 mM NH4Cl in Tris-buffer (pH = 7.2) 
for 5–10  min. Gagp24-reactive cellular immune responses 
in vaccinated mice were assessed by pre-coated interferon-γ 
(IFNγ)-ELISpot plates, according to the manufacturer’s protocol 
(Mabtech, Nacka Strand, Sweden). Splenocytes in RPMI 1640 
with 10% FBS and gensumycin were seeded at cell density 1 × 106, 
5 ×  105, and 2.5 ×  105 in volume 100 μl per well in duplicates 
and restimulated with peptides in concentration 4  μg/μl for 
26–28 h at 37°C. The peptides comprised the entire Gagp24 and 
were 15-mers with 11-amino acid overlaps between sequential 
peptides. The peptides were divided in pools 1–5, as described by 
Trumpfheller et al., and each pool consisted of 9–12 peptides (45). 
Pool 1 consisted of peptides spanning amino acid 125–183 of Gag 
polyprotein precursor; pool 2, amino acid 173–231; pool 3, amino 
FigUre 1 | schematic drawings of the constructs included in the 
study. (a) Drawing of the designed p62/SQSTM1-containing vaccine 
construct. The 3-prime end of DNA of p62 is connected to the antigenic unit 
via a linker region (L) encoding the amino acids RSTGLSGL. The DNA 
construct was subcloned into the pBudCE4.1 vector, and expression of the 
gene was driven by human cytomegalovirus immediate-early promoter 
(pCMV). Arrow heads indicate unique sites for restriction enzymes. Phox/
Bem 1p (PB1), LC3-interacting region (LIR), and ubiquitin-associated domain 
(UBA) encode some of the functional domains of p62. (B) Overview of all the 
constructs that were included in the study, (i) p62–Gagp24 (Gagp24 isolate 
BH10), (ii) Gagp24, (iii) Gagp24 fused to mCherry, and (iv) p62 fused to 
mCherry. mCherry was included to have the possibility to track p62 and 
Gagp24 by live-cell fluorescence microscopy and was subcloned into the 
antigenic unit. All constructs were subcloned into the pBudCE4.1 vector 
downstream of pCMV.
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acid 221–279; pool 4, amino acid 269–327; and pool 5, amino acid 
317–363. In addition, the MHC class I-restricted, H-2 Kd-binding 
peptide AMQMLKETI (amino acid 197–205) (GenScript) was 
used for restimulation of CD8+ T cells (46). Splenocytes cultivated 
in medium only and splenocytes from mice that had received 
NaCl before electroporation were used as negative controls. The 
number of IFNγ+ spots was determined by CTL ELISPOT reader 
(CTL Europe GmbH, Bonn, Germany) in “Smart Count” mode. 
Before enumeration of the samples, the software was trained to 
set a threshold for spots that should be considered as positive, 
by analyzing several wells of negative controls as well as strongly 
positive samples. Occasionally, negative control wells contained 
a few spots (1–13), which were not substracted from the samples. 
All counted spots for the p62–Gagp24 and Gagp24 group of mice 
are presented.
statistical analyses
Statistical analyses were performed using GraphPad Prism ver-
sion 4. Differences between treatment groups were analyzed by 
using two-tailed t-test or Mann–Whitney test. P-values ≤0.05 
were considered significant.
resUlTs
Design of sQsTM1/p62-containing 
Vaccine construct
We designed a novel vaccine strategy based on the fusion of 
antigen to the selective autophagy receptor sequestosome 1 
(SQSTM1)/p62, which should enable targeted antigen delivery 
to the autophagy pathway. Our hypothesis was that this approach 
would result in enhanced antigen presentation on MHC class 
I and class II molecules and thereby increased generation of 
antigen-specific CD8+ and CD4+ T cells, respectively. Therefore, 
we generated a hybrid vaccine DNA construct in which the 
gene encoding the antigen was fused with the p62 gene. The p62 
protein is known to be selectively sequestered into autophagy by 
its LIR [microtubule-associated protein 1 light chain 3 (LC3)-
interacting region] domain, which binds to LC3, a marker protein 
of autophagy (47). Other functional domains of p62 include 
Phox/Bem 1p (PB1), which can polymerize p62 or interact with 
other PB1-containing proteins (48, 49) and ubiquitin-associated 
domain (UBA) that binds ubiquitin and polyubiquitin (50–52) 
(Figure 1A). Aiming not to affect the function of the N-terminal 
PB1 domain, DNA encoding the test antigen (HIV-1-derived 
Gagp24) was connected via a short linker (L) to the 3-prime end 
of p62 (Figure 1A). To be able to track p62 and Gagp24 by live 
microscopy, we subcloned DNA encoding the fluorescent mol-
ecule mCherry into the antigenic unit (Figures 1A,B). Gagp24 
and mCherry alone were used as controls (Figure 1B).
Vaccine antigen Fused to p62 is Delivered 
into the autophagy Pathway
To examine the localization of the various constructs relative to the 
autophagy pathway, we made use of HEK293 cells stably express-
ing EGFP fused to the autophagy marker protein LC3 (44). Upon 
induction of autophagy, EGFP–LC3 will be observed as punctuated 
or vesicular structures (53–55). Upon fusion of autophagosomes 
with endosomes and lysosomes, the luminal content is exposed 
to gradual decrease in pH (56). EGFP is acid-labile with a pKa of 
6.0 (57). Therefore, to be able to detect EGFP–LC3 throughout 
the autophagy pathway and hinder degradation of our constructs 
by pH-regulated enzymes, the samples were treated with NH4Cl 
to block acidification of intracellular vesicles, before analysis by 
microscopy (Figure S1 in Supplementary Material).
Human immunodeficiency virus-1 Gag (precursor of Gagp24) 
has been found in complexes with LC3 (58). As we aimed to 
evaluate the effect of p62-mediated targeting to autophagy, we 
needed to exclude that Gagp24 was able to reach this pathway on 
its own. Therefore, in the first set of experiments, we transfected 
DNA encoding Gagp24–mCherry into EGFP–LC3+ HEK293 
cells. Analysis by live-cell confocal microscopy revealed a weak, 
mostly uniform mCherry signal throughout the cell, suggest-
ing that Gagp24 did not sort into any particular compartment 
(Figures  2A and 3A, upper panels). In contrast, transfection 
of DNA encoding p62–mCherry resulted in highly fluorescent 
mCherry positive puncta in the cytoplasm (Figure  2A, lower 
panels), consistent with previous reports (33). Whereas there 
was no enrichment of Gagp24–mCherry in EGFP–LC3+ struc-
tures, more than 95% of the p62–mCherry puncta co-localized 
with EGFP–LC3+ (Figures 2A,C). Next, we examined whether 
p62 also could target Gagp24 into the autophagy pathway. 
EGFP–LC3+ HEK293 cells were transfected with DNA plasmids 
encoding Gagp24 or p62–Gagp24 and cultivated before fixation 
and immunostaining of Gagp24. In cells transfected with Gagp24 
FigUre 2 | gagp24 distributes throughout the cellular cytoplasm.  
(a) EGFP–LC3+ HEK293 cells were transfected with DNA plasmids encoding 
Gagp24–mCherry or p62–mCherry. After 20 h, 10 mM NH4Cl was added to the 
wells in order to prevent acidification of vesicles and retain the EGFP fluorescent 
signal. The cells were incubated for additional 24 h before analysis by live-cell 
confocal microscopy. The corner insets show high magnification of framed 
areas. Scale bars, 5 μm. Images are representative selections from three 
independent experiments. (B) DNA encoding Gagp24 or p62–Gagp24 was 
transfected into EGFP–LC3+ HEK293 cells. After 20 h, 10 mM NH4Cl was 
added to the wells and incubated for additional 24 h before fixation and staining 
with anti-Gagp24 antibody. The corner insets show high magnification of framed 
areas. Scale bars, 10 μm. Images are representative selections from three 
independent experiments. (c) Quantification of double-positive puncta per cell 
for EGFP–LC3 and Gagp24–mCherry as well as EGFP–LC3 and p62–mCherry 
in the experiment outlined in (a). Mean values with SEM of three independent 
experiments are presented. (D) Quantification of double-positive puncta for 
EGFP–LC3 and Gagp24 as well as EGFP–LC3 and p62–Gagp24 per cell in the 
experiments outlined in (B): 79% of the p62–Gagp24 puncta were positive for 
LC3 in NH4Cl-treated cells. Mean values with SEM of three independent 
experiments are presented.
FigUre 3 | p62 delivers fused antigen into autophagosomes. (a) 
HEK293T cells were co-transfected with DNA plasmids encoding  
Rab7-EGFP and Gagp24–mCherry or p62–mCherry. After 20 h, 10 mM 
NH4Cl was added to the wells to prevent acidification before incubation for 
additional 24 h and live-cell confocal microscopy. The corner insets show 
high magnification of framed areas. Scale bars, 10 μm. Images are 
representative selections from three independent experiments. (B) 
Quantification of double-positive puncta per cell for Rab7-EGFP and 
Gagp24–mCherry as well as Rab7-EGFP and p62–mCherry in the 
experiment outlined in (a). Mean values with SEM of three independent 
experiments are presented.
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alone, Gagp24 was distributed evenly throughout the cell and was 
largely excluded from EGFP–LC3+ puncta (Figure  2B, upper 
panels). In contrast, but similar to what we observed for p62–
mCherry, p62–Gagp24 accumulated in distinct puncta, which 
showed overt co-localization with EGFP–LC3 (Figure 2B, lower 
panels). Quantification of microscopy images revealed that about 
80% of the p62–Gagp24 puncta were positive for EGFP–LC3 
(Figure 2D). These data suggest that p62 can deliver proteins that 
are fused to its C-terminus into the autophagy pathway.
Because both LC3 and p62 can be present as aggregates in 
the cytosol (32, 55), we wanted to confirm that fusion constructs 
of p62, indeed, was sequestered in autophagic vesicles. For this 
purpose, we used Rab7-EGFP, a marker of late endosomes, 
FigUre 4 | Modulators of autophagy affect p62–gagp24 but not 
gagp24. (a) DNA plasmids encoding Gagp24 or p62–Gagp24 were 
transiently transfected into HEK293T cells. At 20 h post-transfection, the 
cells were exposed for 12 h to treatments that modulate autophagy, 5 μM 
rapamycin (induces autophagy), amino acid starvation by incubation in Earle’s 
balanced salt solution (EBSS) (induces autophagy), incubation with 10 mM 
NH4Cl (hinders protein degradation in mature autophagosomes), or 10 mM 
3-methyladenine (3-MA) (hinders initiation of autophagy) before making cell 
lysates. The lysates were analyzed for changes in Gagp24 levels by western 
blotting, using a monoclonal anti-Gagp24 antibody for detection. Labeling 
with an anti-β tubulin antibody was used to compensate for loading 
differences. The experiment was performed twice and the results were 
similar. (B) Results of the experiment outlined above, presented in a 
histogram, showing band density of Gagp24 normalized to that of β-tubulin. 
Each column shows mean values with SEM of pooled data from two 
independent experiments.
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lysosomes as well as mature autophagosomes that have fused with 
endosomes or lysosomes (i.e., amphisomes and autolysosomes, 
respectively) (59, 60). HEK293T cells were co-transfected with 
DNA encoding Rab7-EGFP and Gagp24–mCherry or with Rab7-
EGFP and p62–mCherry before live-cell confocal microscopy. 
There was no co-localization between Rab7-EGFP and Gagp24–
mCherry relative to the background [Figure 3A (upper panel) 
and Figure 3B]. In contrast, more than 80% of the p62–mCherry 
puncta co-localized with Rab7-EGFP [Figure 3A (lower panel) 
and Figure  3B]. Thus, the dominant fraction of p62–mCherry 
co-localized with Rab7, most likely indicating mature autophagic 
vesicles. Collectively these data suggest that fusion to p62 can 
be utilized as a means to efficiently deliver vaccine antigens into 
LC3- and Rab7-positive vesicles, i.e., the autophagy pathway.
p62 alters the level of Vaccine antigen
To examine whether p62 altered the level and intracellular 
turnover of Gagp24, HEK293T cells were transfected with DNA 
encoding Gagp24 or p62–Gagp24 before treatment with induc-
ers or inhibitors of autophagy. Both rapamycin and amino acid 
deprivation are strong inducers of autophagy. NH4Cl prevents 
endolysosomal acidification and thereby the activity of low pH-
dependent proteases derived from endosomes and lysosomes 
upon autophagosomal maturation. 3-methyladenine (3-MA) 
is an inhibitor of phosphoinositide 3-kinases including Vps34, 
which is required for the initiation of autophagy (61, 62). Western 
blotting of lysed cells revealed that the levels of Gagp24 alone 
was unaffected by all treatments (Figures  4A,B). In contrast, 
the level of p62–Gagp24 correlated with the level of autophagy, 
i.e., the inducers of autophagy (rapamycin or amino acid dep-
rivation) reduced the level of p62–Gagp24, whereas inhibitors 
(NH4Cl or 3-MA) enhanced the level (Figures 4A,B). These data 
are consistent with the observations made by microscopy, i.e., 
p62 altered the localization of Gagp24 and targeted antigen to 
LC3- and Rab7-positive vesicles. Furthermore, the data show that 
p62–Gagp24 levels were regulated by endolysosomal activities 
and mechanisms known to control autophagic activity.
coupling to p62 Prevents rapid 
Degradation of hiV-1 gagp24  
in the cytosol
We hypothesized that the formation of aggregates and the target-
ing of antigen into the autophagy pathway should protect the 
antigen from rapid degradation in the cytosol by the proteasome. 
In order to test this, half of the transfected HEK293 cells were 
treated for 1, 3, and 6 h with MG132, an inhibitor of the protea-
some (63). The cell lysates were subjected to western blotting and 
protein was detected using an anti-Gagp24 antibody (Figure 5A). 
Analysis of the density of the bands revealed that inhibition of 
the proteasome even for only 1 h led to a significant increase of 
Gagp24 in the Gagp24-transfected cells (Figure 5B). In contrast, 
there was no significant increase in the level of p62–Gagp24 in 
untreated and MG132-treated cells (Figure 5B). These data are 
consistent with a model where fusion with p62 delivers Gagp24 
into the autophagy pathway and thereby prevents it from rapid 
degradation by the proteasome.
antigen Fusion to p62 results in increased 
generation of gagp24-specific  
T cells In Vivo
As the p62 fusion directed the antigen to autophagy and pre-
vented it from rapid degradation, we wanted to examine whether 
the fusion construct would result in enhanced T cell responses 
in vivo. DNA plasmids encoding Gagp24 or p62–Gagp24 were 
injected into the dermis of mice before electroporation (which 
was used to enhance uptake of the DNA). Splenocytes were 
harvested at different time points after immunization. To evalu-
ate T  cell responses, we used a library of 15-amino acid long 
peptides with an 11-amino acid overlap between sequential 
peptides covering the full Gagp24 sequence. The peptides were 
divided into 5 pools each containing 9–12 peptides. Each pep-
tide pool was added to splenocytes, and responding T cells were 
FigUre 5 | p62 protects gagp24 from degradation by the 
proteasome. (a) DNA plasmids encoding Gagp24 or p62–Gagp24 were 
transiently transfected into HEK293T cells. At 20 h after transfection, the cells 
were left untreated or were treated with 5 μM MG132, an inhibitor of the 
proteasome, for 1, 3, or 6 h before making cell lysates. The lysates were 
analyzed by western blotting using an anti-Gagp24 antibody. Labeling with 
an anti-β tubulin antibody was used to compensate for loading differences. 
The experiment was performed three times, and the results were similar.  
(B) Results of the experiment outlined above, shows band density of Gagp24 
normalized to that of β-tubulin. Each column shows mean values with SEM of 
pooled data from three independent experiments. P-values were calculated 
by two-tailed t-test.
FigUre 6 | Fusion of gagp24 to p62 results in increased number of 
gagp24-reactive T cells in mice.  
(Continued)
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detected by IFNγ-ELISpot. Because of the length of the peptides, 
they were expected to bind to MHC class II molecules and be 
indicative of CD4+ T cell responses, and peptides in pools 1 and 
3 have previously been shown to stimulate CD4+ T cells (45). 
However, CD8+ T cell responses cannot be excluded as peptides 
being up to 13-amino acids have been shown to restimulate 
CD8+ T cells (64). Moreover, the 15-mers may be trimmed into 
8–10 amino acid long peptides, which is the typical length for 
MHC class I-binding. Immunization with Gagp24 resulted in 
low number of IFNγ+ T cells reactive toward peptide pools 1, 
3, 4, and 5 (Figures  6A,B). In comparison to Gagp24 alone, 
immunization with p62–Gagp24 resulted in a tendency of more 
IFNγ+ T cells toward all peptide pools except from peptide pool 
1 (Figures 6A,B). Furthermore, there was a significant increase 
in IFNγ+ T cell responses toward pool 2 and pool 3 peptides at 
both 5 and 18  weeks (Figures  6A,B). The highest number of 
IFNγ+ T cells was observed toward peptide pool 2, which cov-
ered a previously defined Gag197–205 MHC class I-restricted 
peptide (46).
In another set of analysis, we registered the responsiveness 
of each immunized mice toward a number of peptide pools. 
An arbitrary value of 20 IFNγ+ SFC/106 splenocytes was set as 
threshold, and only responses above this number toward a given 
peptide pool were included. In order to include as many mice 
FigUre 8 | Fusion of gagp24 to p62 increased the number of  
gagp24-reactive cD8+ T cells. BALB/c mice were immunized once by 
intradermal injection on the left and right flank of 25 μl of 12.5 μg DNA 
plasmid encoding Gagp24 or p62–Gagp24 before electroporation. 
Splenocytes were harvested after 5 or 18 weeks and subjected to 
IFNγ-ELISpot for enumeration of CD8+ T cells, specific for the Gagp24 class I 
peptide sequence AMQMLKETI (46). Mean values with SEM are presented. 
Week 5: n = 3–6 mice/group and week 18: n = 7 mice/group. P-values were 
calculated by two-tailed t-test.
FigUre 7 | Mouse responsiveness to number of gagp24-derived 
peptide pools. The graph presents the number of peptide pools that each 
immunized BALB/c mouse responded to with IFNγ+ T cells. The mice were 
immunized once with an intradermal injection on the left and right flank with 
25 μl of 12.5 μg DNA plasmid encoding Gagp24 or p62–Gagp24 before 
electroporation. Splenocytes were harvested after 5, 7, or 18 weeks and 
subjected to IFNγ-ELISpot for enumeration of Gagp24-reactive T cell 
responses toward five different Gagp24-derived peptide pools described in 
the legend of Figure 6. In the analysis, 20 IFNγ+ SFC/106 splenocytes were 
set as threshold, and only responses toward a given peptide pool that were 
above the threshold were included. Gagp24, n = 16 mice; p62–Gagp24, 
n = 14 mice. The P-value was calculated by Mann–Whitney test.
BALB/c mice were immunized once by intradermal injection on the left and 
right flank with 25 μl of 12.5 μg DNA plasmids encoding Gagp24 or  
p62–Gagp24 before electroporation. Splenocytes were harvested after  
5 (a) or 18 (B) weeks and subjected to IFNγ-ELISpot for enumeration of 
IFNγ-producing Gagp24-reactive T cells toward peptides spanning Gagp24. 
The peptides were 15-mers and were divided in pools 1–5, each pool 
containing 9–12 peptides. Pool 1 consisted of peptides spanning amino acid 
125–183 of Gag polyprotein precursor; pool 2, amino acid 173–231; pool 3, 
amino acid 221–279, pool 4, amino acid 269–327; and pool 5, amino acid 
317–363. Mean values with SEM are shown, week 5: n = 3–6 mice/group 
and week 18: n = 7 mice/group. P-values were calculated by two-tailed t-test.
FigUre 6 | continued
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as possible in the analysis, we plotted data obtained 5, 7, and 
18 weeks after immunization and found that the Gagp24 group 
elicited responses against 1–5 different peptide pools (median 
value 2) (Figure 7). In the p62–Gag24 group, all mice showed 
responses toward three or more peptide pools (median value 
4.5), which were significantly different from the responses of the 
Gagp24 group (Figure 7). The analysis shows that in comparison 
to antigen delivered alone, fusion to p62 resulted in more IFNγ+ 
T cells, which specificity covered 4.5 of the peptide pools. This 
may imply that fusion to p62 enhances the presentation of anti-
genic peptides. The peptide repertoire may be identical to that 
generated following immunization with Gagp24. Alternatively, 
fusion to p62 promotes the presentation of a more diverse peptide 
repertoire with the consequent development of a broader pool of 
HIV-1 Gagp24-specific T cells.
Fusion to p62 increased the number of 
gagp24-reactive cD8+ T cells
Splenocytes examined for their responses toward 15-mer 
peptides spanning Gagp24 (described in the previous section) 
were also tested for their recall response toward the MHC class 
I-restricted peptide Gag197–205 (46). Enumeration of IFNγ+ 
ELISpots showed that p62–Gagp24 induced a significantly higher 
number of IFNγ-producing CD8+ T cells compared to Gagp24 
alone (Figure 8). Taken together, analyses of the T cell responses 
suggest that fusion of antigen to p62 represents an efficient strat-
egy to increase antigen-reactive CD4+ as well as the CD8+ T cell 
responses.
DiscUssiOn
In this study, we show that coupling of HIV-1 Gagp24 to p62 
promotes the magnitude of the IFNγ+ T cell response. To our 
knowledge, this is the first study that makes use of antigen fusion 
to p62 to promote vaccine responses. By this strategy, the antigen 
was efficiently delivered to the autophagy pathway. It is accepted 
that the autophagy pathway delivers peptides for presentation on 
MHC class II molecules (13, 21–25). That the pathway also con-
tributes with antigen for presentation on MHC class I molecules 
is less established (10, 14).
Autophagy can intercept pathogen invasion of the cytoplasm, 
and both virus and bacteria can be found inside autophagic 
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compartments. Moreover, there is cross talk between autophagy 
and pattern recognition receptors, and activation of autophagy 
has been linked to Th1 cytokines (15). Based on these and other 
findings, we hypothesized that autophagy is involved in antigen 
delivery to MHC class I molecules. In line with this are the stud-
ies that show enhanced CD8+ T cell responses following delivery 
of enriched antigen-containing autophagic vesicles or antigen 
donor cells with enhanced autophagy (28–31). p62, being a clas-
sical autophagic cargo receptor, has been implied in the targeting 
of pathogens to autophagic degradation. Its activity has also been 
addressed in delivery of ubiquitinated antigen into autophago-
somes and subsequent autophagy engaged cross-presentation of 
antigen to CD8+ T cells (30). Based on these reflections and data, 
we hypothesized that p62-mediated delivery of antigen into the 
autophagy pathway may be a viable strategy to promote induction 
of antigen-specific CD4+ and CD8+ T cells.
Whereas most studies have fused protein to the N-terminal end 
of p62, we chose to fuse mCherry and Gagp24 to its C-terminal 
end. Immunofluorescence microscopy and western blotting 
showed that p62 retained the ability to be sequestered into the 
autophagy pathway suggesting that the LIR domain was available 
for binding to LC3. Moreover, by fusion to the C-terminal end of 
p62, we anticipated that the PB1 domain would maintain its abil-
ity to polymerize with PB1 domain-containing proteins, such as 
atypical protein C kinases and the protein kinase MEKK3. These 
interactions are required for NF-κB activation in response to 
inflammatory signals (such as TNFα and IL-1) mediated by TNF 
receptor-associated factor 6 (TRAF6) and receptor-interacting 
protein (RIP) (65–67), which may be beneficial to promote 
vaccine-induced immunity.
Viral proteins, including the precursor of HIV-1 Gagp24 (Gag), 
have been reported to associate with the autophagy pathway (58). 
In our experiments, the protein level of Gagp24 was only affected 
upon incubation with the proteasome inhibitor, suggesting that 
Gagp24 was processed by the proteasome and not by autophagy. 
In contrast, the level of p62–Gagp24 varied dependent on whether 
autophagy was induced or inhibited, verifying that p62 delivered 
the antigen into the autophagy pathway. By fusion of Gagp24 to 
p62, we observed an enhanced number of antigen-specific IFNγ+ 
T cells recognizing the peptide pools 2, 3, 4, and 5 (i.e., peptides 
covering 80% of the Gagp24 protein sequence). Our data suggest 
that by fusing antigen to p62 and thereby targeting to autophagy 
one can increase the magnitude of the IFNγ+ T cell response. 
The results bear similarities with the data of Jin et al., showing 
that a DNA vaccine based on antigen fusion to LC3 induced, 
although to a low extent, an antigen-specific CD4+ and CD8+ 
T cell response and increased their magnitude (19). There could 
be several explanations for why fusion to p62, rather than to LC3, 
appears to be a better strategy for the induction of T cell responses. 
Constructs of p62 with deletions or mutations in domains that 
mediate signaling, and in the domain (LIR domain) that mediates 
targeting to autophagy, may identify the mechanisms behind the 
enhanced T cell responses.
Use of an HIV-1-derived MHC class I-restricted peptide 
(AMQMLKDTI) revealed that fusion to p62 can promote CD8+ 
T cell responses. Because 15-mer peptides may be trimmed and 
MHC class I molecules have been reported to bind peptides 
longer than 8–10 amino acids (64), the observed IFNγ+ T cell 
responses towards the peptide pools may also include CD8+ 
T cells. Following delivery of DNA into mice, the p62-containing 
construct (Figure 9A) may promote T-cell-mediated immunity 
by different mechanisms, which are not mutually exclusive, (i) 
DCs may be transfected, and the expressed vaccine protein is by 
p62 selectively sequestered in autophagosomes (Figures 9A,B). 
Autophagosomes fuse with endocytic compartments (68), and 
the antigen may be processed in a TAP-dependent or independ-
ent manner before loading on MHC class I molecules. (ii) Cell 
types other than DCs, such as epithelial cells and fibroblasts, 
may be transfected and will function as antigen donor cells. The 
expressed vaccine protein is sequestered in autophagosomes, 
which may be secreted (69) and internalized by DCs specialized 
for cross-presentation (Figures 9A,C). Alternatively, dying cells 
containing autophagosomes with vaccine protein are engulfed 
by DCs before the antigen is processed and presented on MHC 
class I molecules to CD8+ T cells (Figure 9C). Moreover, it cannot 
be excluded that the increased number of antigen-specific CD8+ 
T cells is caused by an enhanced number of CD4+ T cells available 
for help. Along these lines, it should be mentioned that Schmid 
et al. observed some co-localization between LC3 and molecules 
characteristic for MHC class I loading compartments, although 
antigen-targeting to autophagy by LC3 did not promote CD8+ 
T cell stimulation in vitro (24). Several other reports implicate 
that autophagy can enhance presentation of MHC class I peptides 
and priming of CD8+ T cells (28–31). Based on these studies, it 
is reasonable to believe that fusion to p62 may have some direct 
effect on antigen presentation and activation of CD8+ T cells in 
our experiments.
The number of epitopes that are targeted by CD8+ T cells 
(i.e., the breadth of the response) appears to be important for 
viral control of HIV-1. Post hoc analyses of participants of the 
HTVN 502 vaccine trial showed that individuals in whom the 
vaccine had induced T cell responses targeting ≥3 epitopes of 
Gag, achieved a lower viral load after HIV infection than subjects 
without Gag responses (71, 72). A broad T cell response may be 
particularly important in order to target different viral strains 
and escape mutants and in order to enhance the probability 
of targeting subdominant epitopes associated with protection 
against the virus (71, 73). Along these lines, many types of can-
cers are characterized by point mutations in endogenous proteins 
and the ability to escape an immune response by immunoediting 
(74, 75). Thus, the ability to induce a response toward a broad 
number of epitopes and proteins is expected to be necessary for 
a vaccine to be efficient against HIV-1 and in therapeutic cancer 
vaccination.
Mice in the p62–Gagp24 group generated a higher number 
of IFNγ+ T cells specific for more peptide pools than mice in the 
Gagp24 group. Further studies are needed to determine whether 
our approach indeed enhances the clonal diversity of the T cell 
response, and if so, whether that applies to both the CD4+ and 
CD8+ T cell responses. Nevertheless, the ability of p62 to divert 
the antigen away from rapid proteasomal degradation and expose 
it to another set of proteolytic enzymes does have potential 
advantages for generation of antigen-specific T cell responses. 
Exposure to proteasome inhibitors has resulted in enhanced 
FigUre 9 | schematic drawing of proposed mechanisms of the p62-containing vaccine construct. (a) Antigen is couplet to the C-terminus of p62. 
Lipidated LC3, LC3-II, is bound to the phagophore, which is a membrane precursor of the autophagosome. The LIR motif of p62 enables interaction with LC3-II. 
The phagophore expands, eventually seals, and forms an autophagosome. In this manner, p62 can selectively deliver couplet antigen into autophagosomes. (B) In 
mice, when the vaccine is delivered as DNA into the dermis, DCs may be transfected and express the vaccine protein. The vaccine protein is by p62 sequestered in 
autophagosomes or may first accumulate in DC aggresome-like structures (DALIS) in the cytosol. DALIS are selectively removed from the cytosol by autophagy. 
Autophagosomes fuse with endocytic compartments, and the antigen is processed in a TAP-dependent or independent manner before its peptides are loaded on 
MHC class I molecules and transported to the cell surface. (c) Alternatively, delivered DNA is taken up by cells, such as fibroblasts and epithelial cells. Expressed 
vaccine protein is sequestered in autophagosomes of these cells, which now serve as antigen donor cells (1). Dying cells with vaccine-containing autophagosomes 
are engulfed by DCs (2a and 3). Alternatively, autophagosomes, which may have undergone maturation, are secreted and internalized by cross-presenting DCs (2b 
and 3). The antigen is processed and loaded on MHC class I molecules via pathways that remain to be identified (3). It is well established that autophagy contributes 
to the pool of cytoplasm-derived antigens displayed on MHC class II molecules (24). Moreover, pathogens, soluble antigens, extracellular vesicles as well as dying 
cells may be internalized by DCs, and MHC-II-destined peptides are generated by endo/lysosomal proteolysis (9).
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presentation of both dominant and subdominant HIV-1 epitopes 
(76). Dinter et  al. showed that proteases present in the cytosol 
and the endolysosomal system can differently affect the peptide 
repertoire (76). Indeed, some peptides were more efficiently 
generated by enzymes present in the endolysosomal pathway. 
Moreover, inhibiting rapid degradation of model antigens has 
been shown to enhance cross-priming of CD8+ T cells by the 
transfer of proteasomal substrate to APCs (70).
In addition to the importance of a broad T cell response, focus 
has recently been put into the need of inducing T cell responses 
toward subdominant epitopes. For example,  controllers of 
HIV-1 show enhanced frequency of cytotoxic CD8+ T  cells 
specific for subdominant epitopes (71). To induce such T cell 
responses, the pattern of immunodominance may have to be 
broken. Therefore, there is a need for the development of novel 
vaccine strategies. We found that antigen fusion to p62 rescued 
the antigen from rapid proteasomal degradation and enhanced 
antigen-specific IFNγ+ T  cell responses. Our vaccine strategy 
could be a viable strategy to promote the generation of protec-
tive T cell responses.
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